11:36 AM
 | 
Feb 01, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eyenovia planning NDA in 1Q20 for microdose ophthalmic solution to induce mydriasis

Eyenovia Inc. (NASDAQ:EYEN) plans to submit an NDA to FDA in 1Q20 for MicroStat to induce mydriasis (dilation of the pupil) after the product met the primary endpoint in the Phase III MIST-1 trial. MicroStat is a fixed-microdose ophthalmic solution of 2.5% phenylephrine...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >